



Contents lists available at ScienceDirect

Schizophrenia Research

journal homepage: www.elsevier.com/locate/schres

Analysis of differentially methylated regions in great apes and extinct hominids provides support for the evolutionary hypothesis of schizophrenia

Niladri Banerjee^{a,b}, Tatiana Polushina^{a,b}, Francesco Bettella^{c,d}, Vidar M. Steen^{a,b}, Ole A. Andreassen^{c,d}, Stephanie Le Hellard^{a,b,*}

^a NORMENT - K.G. Jebsen Center for Psychosis Research, Department of Clinical Science, University of Bergen, Bergen, Norway

^b Dr. Einar Martens Research Group for Biological Psychiatry, Department of Medical Genetics, Haukeland University Hospital, Bergen, Norway

^c NORMENT - K.G. Jebsen Center for Psychosis Research, Institute of Clinical Medicine, University of Oslo, Oslo, Norway

^d NORMENT - K.G. Jebsen Centre, Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway

ARTICLE INFO

Article history:

Received 20 March 2018

Received in revised form 12 October 2018

Accepted 22 November 2018

Available online xxx

Keywords:

Schizophrenia

Evolutionary hypothesis

Epigenetics

Differentially methylated regions

Primates

Neanderthals

ABSTRACT

Introduction: The persistence of schizophrenia in human populations separated by geography and time led to the evolutionary hypothesis that proposes schizophrenia as a by-product of the higher cognitive abilities of modern humans. To explore this hypothesis, we used here an evolutionary epigenetics approach building on differentially methylated regions (DMRs) of the genome.

Methods: We implemented a polygenic enrichment testing pipeline using the summary statistics of genome-wide association studies (GWAS) of schizophrenia and 12 other phenotypes. We investigated the enrichment of association of these traits across genomic regions with variable methylation between modern humans and great apes (orangutans, chimpanzees and gorillas; great ape DMRs) and between modern humans and recently extinct hominids (Neanderthals and Denisovans; hominid DMRs).

Results: Regions that are hypo-methylated in humans compared to great apes show enrichment of association with schizophrenia only if the major histocompatibility complex (MHC) region is included. With the MHC region removed from the analysis, only a modest enrichment for SNPs of low effect persists. The INRICH pipeline confirms this finding after rigorous permutation and bootstrapping procedures.

Conclusion: The analyses of regions with differential methylation changes in humans and great apes do not provide compelling evidence of enrichment of association with schizophrenia, in contrast to our previous findings on more recent methylation differences between modern humans, Neanderthals and Denisovans. Our results further support the evolutionary hypothesis of schizophrenia and indicate that the origin of some of the genetic susceptibility factors of schizophrenia may lie in recent human evolution.

© 2018 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

1. Introduction

Schizophrenia is a psychiatric disorder with a prevalence rate of 2.7–8.3/1000 persons (Messias et al., 2007) and heritability estimated between 60 and 90% (Cardno et al., 1999; Lichtenstein et al., 2009; Skre et al., 1993; Sullivan et al., 2003). It occurs at quite similar rates across populations worldwide (Ayuso-Mateos, 2002; Brüne, 2004; WHO, 1973) and written records describing its symptoms exist dating

back 5000 years (Jeste et al., 1985). This consistent persistence of the disease despite reduced fecundity (Brüne, 2004; Essen-Möller, 1959; Lewis, 1958; Macsorley, 1963; Nichols, 2009; Power et al., 2013; Stevens, 1969) and increased mortality is a paradox (Bassett et al., 1996; Brown, 1997; Larson and Nyman, 1973), since the reduced fecundity of patients afflicted with schizophrenia does not appear to eliminate the disease from the population (Power et al., 2013). Part of the reason may be due to afflicted individuals reproducing prior to the onset of the disease (Markow, 2012). Another contributing factor could be that schizophrenia risk variants may have provided an advantage to the kin of the affected by conferring superior creative and intellectual abilities upon them (Kyaga et al., 2011; Nichols, 2009). To explain the constant occurrence of the disease, the concept of an evolutionary basis for the disorder was initially put forward by Essen-Möller (1959) and Huxley et al. (1964). The version that is best known, was

* Corresponding author at: Department of Clinical Medicine, Laboratory Building, Haukeland University Hospital, N-5021 Bergen, Norway.

E-mail addresses: niladri.banerjee@uib.no (N. Banerjee), tatiana.polushina@uib.no (T. Polushina), francesco.bettella@medisin.uio.no (F. Bettella), vidar.martin.steen@helse-bergen.no (V.M. Steen), o.a.andreassen@medisin.uio.no (O.A. Andreassen), stephanie.hellard@uib.no (S. Le Hellard).

however postulated by TJ Crow (Crow, 1997, 1995) who proposed the so-called evolutionary hypothesis of schizophrenia that suggests that the disease is a consequence of human evolution: the higher cognitive abilities of modern-day humans, including language, may predispose to psychiatric illnesses such as schizophrenia (Crow, 2008, 2000, 1997).

In the post-genomic era (Lander et al., 2001; Venter et al., 2001), emerging lines of evidence are lending support to this hypothesis. Crespi et al. (Crespi et al., 2007) were among the first to show that genes with evidence of recent positive selection in humans are also implicated more frequently in schizophrenia. More evidence has been provided by studies based on comparative genomics (Pollard et al., 2006; Srinivasan et al., 2016; Xu et al., 2015), a field in which genomes of progressively older species are compared to identify substitutions and mutations that help estimate divergence between the species. For instance, a group of regions defined by negative Neanderthal selective sweep (NSS) scores describe the selective evolution of genomic regions in modern-day humans over Neanderthals (Burbano et al., 2010; Green et al., 2010). These regions were shown by (Srinivasan et al., 2016) to be enriched for schizophrenia risk markers, in line with the evolutionary hypothesis of schizophrenia. Other regions known as human accelerated regions (HARs) (Gittelman et al., 2015; Pollard et al., 2006; Xu et al., 2015), first described by (Pollard et al., 2006), show accelerated evolution in humans compared to primates or mammals. HARs have also provided some evidence of enrichment of association with schizophrenia (Xu et al., 2015), but these findings may have been driven by a few genes since they were not replicated using a polygenic approach (Srinivasan et al., 2017, 2016).

While several studies have looked at the evolution of the genome (Bird et al., 2007; Bush and Lahn, 2008; Gittelman et al., 2015; Paaby and Rockman, 1990; Pollard et al., 2006), there are reports that the epigenome is evolving as well (Gokhman et al., 2014; Hernando-Herraez et al., 2015, 2013; Mendizabal et al., 2014; Molaro et al., 2011). This provides new insights into events leading to the speciation and divergence of modern humans. The epigenome refers to the layer of chemical modifications, such as methylation and histone modifications, to the genome that regulate gene expression (Bernstein et al., 2007; Kundaje et al., 2015; Rivera and Ren, 2013). For instance, (Gokhman et al., 2014) compared the methylomes of humans with Neanderthals and Denisovans. They reported that while 97% of the methylome was comparable between humans, Neanderthals and Denisovans, some regions showed differential methylation between the three hominids. Previously (Banerjee et al., 2018), we analysed the differentially methylated regions (DMRs) identified for Neanderthals, Denisovans and modern humans by (Gokhman et al., 2014), and found evidence that the regions of the genome with human-specific DMRs harbour relatively more genetic variants associated with schizophrenia than the rest of the genome, i.e. the DMRs were enriched for SCZ markers both at the single-nucleotide polymorphism (SNP) level and at the gene level. These human-specific DMRs thus provide evidence of enrichment of methylation changes in regions harbouring genetic variants associated with schizophrenia, at least since the divergence from Neanderthals and Denisovans (Banerjee et al., 2018).

Here, we sought to determine if evolutionarily older methylation differences can provide a further timeframe for the origin of schizophrenia risk markers in the human lineage. We asked whether we can find epigenetic evidence that the origin of schizophrenia risk markers predates the origins of the Homo genus, i.e. before the divergence of chimpanzees and humans around 6–8 million years ago (MYA) (Glazko and Nei, 2003; Langergraber et al., 2012). We tested this hypothesis by analysing great ape DMRs that trace an evolutionary history of at least 13 million years (Glazko and Nei, 2003; Hasegawa et al., 1985; Rannala and Yang, 2003). We used the same statistical analyses as described by (Lee et al., 2012; Schork et al., 2013; Srinivasan et al., 2016) to test for polygenic enrichment of a set of markers from genome-wide association studies (GWAS). We interrogated regions of the human genome which are hypo- or hyper-methylated in comparison to the corresponding ones

in chimpanzees, gorillas and orangutans for enrichment of genetic variants associated with schizophrenia or other human traits.

2. Materials and methods

2.1. GWAS data

Summary statistics for thirteen different phenotypes were obtained from their respective published GWAS studies: schizophrenia (SCZ) (Ripke et al., 2014), bipolar disorder (BPD) (Sklar et al., 2011), attention deficit hyperactivity disorder (ADHD) (Demontis et al., 2017), rheumatoid arthritis (RA) (Stahl et al., 2010), blood lipid markers (high density lipoprotein (HDL), low density lipoprotein (LDL), triglycerides (TG), total cholesterol (TC)) (Teslovich et al., 2010), blood pressure (systolic blood pressure (SBP), diastolic blood pressure (DBP)) (Ehret et al., 2011), body mass index (BMI) (Locke et al., 2015), height (Wood et al., 2014) and intelligence (Sniekers et al., 2017). For studies published with hg18 coordinates (BPD, SBP, DBP, HDL, LDL, TG, TC, RA), conversion to hg19 was performed using the command line version of the liftOver tool from the UCSC Genome Browser (Karolchik et al., 2014) (http://hgdownload.cse.ucsc.edu/downloads.html#utilities_downloads). For BMI and height SNPs, the genomic coordinates were obtained by mapping them to the assembly of 1000 Genomes Project (1KGP) Phase 1 reference panel SNPs (Durbin et al., 2012).

2.2. Human hypo- and hyper-methylated regions (from great ape DMRs)

These methylated regions were retrieved from the study by Hernando-Herraez et al. (2013), who identified them by comparing the methylation profile of DNA from peripheral blood samples of orangutans, chimpanzees and gorillas to that of humans. They provide both hypo- and hyper-methylated DMRs for humans that were analysed in this study. As these DMRs are identified in the same tissues in all samples, they are considered to represent species-specific methylation differences, not tissue-specific methylation differences (Gokhman et al., 2014). The human hypo- and hyper-methylated DMRs can be used to represent an evolutionary course of history spanning from at least 13 MYA (Glazko and Nei, 2003; Langergraber et al., 2012), when orangutans diverged from the common ancestors, to 6 MYA, when the chimpanzees and humans diverged from each other (Glazko and Nei, 2003; Langergraber et al., 2012). Since our interest was in human-specific enrichment, we focused the analyses on human hypo- and hyper-methylated DMRs. For the sake of brevity and because these human hypo and hyper-methylated DMRs are derived by comparing against great apes, we refer to these DMRs simply as 'great ape DMRs'.

2.3. Differentially methylated regions (DMRs) from Neanderthals, Denisovans and modern humans (hominid DMRs)

As previously described (Gokhman et al., 2014), these methylated regions have been identified by comparing the methylomes of osteoblasts from modern-day humans with those from Neanderthals and Denisovans. Since these human-specific DMRs are obtained by comparing against other hominid species, we refer to them as 'hominid DMRs' to allow easy comparison with great ape DMRs. Gokhman et al. (2014) devised a strategy utilizing information in the form of cytosine (C) to thymine (T) ratios to decipher the ancient methylomes of Neanderthals and Denisovans. Subsequently, they compared the methylomes of Neanderthals, Denisovans and modern humans and inferred the species in which the methylation variation likely took place; this information was used to classify the DMRs as Neanderthal-specific, Denisovan-specific and human-specific. These DMRs represent species-specific methylation (Gokhman et al., 2014).

2.4. Neanderthal selective sweep (NSS) data

We obtained NSS marker data from (Srinivasan et al., 2016). Negative scores for NSS markers indicate positive selection in humans. Markers with such scores were used in the downstream analyses.

2.5. SNP assignment with LDsnpr

The previously published R-based software package LDsnpr (Christoforou et al., 2012) was utilized for assigning SNPs to the respective DMRs using LD (linkage disequilibrium)-based binning at $r^2 \geq 0.8$ in R (Team, 2017). LD-based binning makes it possible to determine whether SNPs from a specific GWAS are in LD with the DMR of interest. Using LD allows the capture of a greater number of relevant SNPs in comparison to an approach where only physically overlapping SNPs are considered. The LD file utilized was in HDF5 format and was constructed from the European reference population of 1KGP and can be publicly downloaded at: <http://services.cbu.uib.no/software/ldsnpr/Download>.

2.6. Enrichment analyses based on stratified quantile-quantile (QQ) plots

QQ plots are an essential method used in GWASs to depict the presence of true signals. They help to visually observe the spread of data and deviations from the null distribution. Under the null hypothesis, no difference is expected between the observed and expected distributions of data. As such, a line of no difference or null line is obtained that is equidistant from both X and Y axes. However, if the null hypothesis were to be false, there would be a deviation of the observed data distribution from the expected data distribution. As described in depth by (Schork et al., 2013), a leftward deflection of the observed distribution from the null line represents enrichment – the greater the leftward deflection, the stronger the enrichment of true signals. This method has been used recently not only to show how specific genomic annotation affects the distribution of disease SNPs with true signals (Schork et al., 2013), but also to demonstrate that regions of recent evolution are enriched for schizophrenia markers (Banerjee et al., 2018; Srinivasan et al., 2016). We took the SNPs that are in LD with the DMR regions and plotted their p -value distributions from various GWASs. The observed p -value distributions were then determined to be enriched or not using conditional Q-Q plots as described by (Schork et al., 2013). Genomic inflation was corrected by λ_{GC} .

2.7. INRICH-based enrichment analysis

The stratified QQ plots provide a visual depiction of data distributions and enrichment of true signals within a stratum of data, but they do not quantify this enrichment. Therefore, we used the INterval ENRICHment (INRICH) analysis tool to statistically quantify the enrichment observed. This pipeline performs permutation and bootstrapping procedures to determine with statistical confidence whether LD-implicated genomic intervals are enriched in specific gene sets (Lee et al., 2012). The INRICH analysis takes into account several potential biases that can otherwise lead to false positives, such as variable gene size, SNP density within genes, LD between and within genes, and overlapping genes in the gene sets. We used the same procedure reported previously (Banerjee et al., 2018; Xu et al., 2015) with SNPs in the extended MHC region and SNPs with MAF < 0.05 excluded from the analysis. Additional details can be found in the Supplementary information.

2.8. Plan of analyses

In this study, we made use of publicly available GWAS data from several phenotypes together with measures of genome evolution. We first intersected regions of great ape DMRs that tagged markers from GWAS of various traits using LDsnpr. We followed this up with polygenic

enrichment testing using stratified QQ plots. Subsequently we performed enrichment analyses using INRICH wherein we tested gene sets flanking great ape DMRs for over-representation of LD-implicated genome intervals. This flowchart is depicted in Supplementary Fig. 1.

3. Results

3.1. Co-localisation of human hypo-methylated regions and genetic variants associated with schizophrenia in the MHC

Following the plan of analysis as depicted in Supplementary Fig. 1, we ascertained whether there is any enrichment of human hypo- and hyper-methylated regions in schizophrenia-associated SNPs. Using previously published methodology (Christoforou et al., 2012), we mapped schizophrenia markers to human hypo-methylated regions (hypo-DMRs) and hyper-methylated regions (hyper-DMRs). Out of a total of ~9.4 million SCZ markers obtained from the GWAS, 10,165 markers tagged hypo-DMRs and 4503 tagged hyper-DMRs.

Fig. 1A shows the conditional QQ plots for schizophrenia markers (all markers, the hypo-DMR set and the hyper-DMR set) including those in the MHC region. For hypo-DMR markers (Supplementary Dataset 1), we observed a significant enrichment as depicted by the leftward deviation. No enrichment was observed for hyper-DMR markers. Since the MHC region is a region of extended linkage disequilibrium, which can bias the enrichment estimates, and since it is the main region of association with schizophrenia, we also tested the enrichment with the MHC region removed (Fig. 1B). Under these conditions there is a trend for enrichment of hypo-DMR markers at higher p -value thresholds, but this enrichment is substantially less than when the MHC is included (Fig. 1A).

3.2. Enrichment of markers is not seen for other human traits

Next, we tested if the human hypo- and hyper-methylated regions are enriched for other human traits and phenotypes. We tested a total of thirteen different phenotypes, full details of which can be found in Section 2.1. Each GWAS had been performed with a different number of genotyped SNPs, and this difference could potentially bias our results. To circumvent this, we created a list of ~2.4 million common SNPs that were genotyped across all the phenotypes investigated in the present study. Only SNPs on this list were used for enrichment analysis.

As can be seen in Fig. 2, no enrichment was observed in any of the traits, with the possible exception of height at higher p -value threshold markers. The common list of markers did not contain the MHC region and as such no enrichment is observed for schizophrenia either.

3.3. Evidence of enrichment for hypo-methylated regions with SNPs at high p -values

The enrichment plots allowed us to visually ascertain enrichment in the datasets. However, they did not give any indication of the statistical robustness of the enrichment. To ascertain if the human hypo- and hyper-methylated regions are statistically enriched for schizophrenia and height markers, we implemented the INRICH pipeline, which performs 10,000 permutations and 5000 bootstrapping calculations, to determine with statistical confidence the enrichment observed (Lee et al., 2012).

The INRICH analysis confirmed a significant ($p < 0.05$) enrichment of association for human hypo-DMRs, but not hyper-DMRs, with schizophrenia at SNPs of higher p -value thresholds ($p < 10e-3$ to $p < 10e-4$) (Fig. 3). This enrichment was at the gene level, and complemented the enrichment observed at the SNP level for higher p -value thresholds (Fig. 1B). Importantly, this enrichment persisted upon testing a pruned schizophrenia dataset (Supplementary Fig. 2). The enrichment was however not significant at the genome-wide threshold ($p < 5 \times 10e-8$) and was much weaker than that observed for hominid DMRs (Fig. 3).




Fig. 1. Enrichment plots of hypo-DMR and hyper-DMR SNPs in schizophrenia Quantile-quantile (QQ) plots of GWAS SNPs for Schizophrenia (SCZ) with the extended MHC region (chr6: 25-35 Mb) unmasked (A) and masked (B). Expected $-\log_{10} p$ -values under the null hypothesis are shown on the X-axis. Observed $-\log_{10} p$ -values are on the Y-axis. The values for all GWAS SNPs are plotted in dark green while the values for SNPs in linkage disequilibrium (LD) with hypo-methylated DMRs are plotted in blue and SNPs in LD with hyper-methylated DMRs are plotted in pink. These DMRs are part of the great ape DMR dataset. A leftward deflection of the plotted p -values from the line for all GWAS SNPs indicates enrichment of true signals – the greater the leftward deflection, the stronger the enrichment. Genomic correction was performed on all SNPs with global lambda. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)




Fig. 2. Enrichment plots of hypo-DMR and hyper-DMR SNPs across multiple traits Thirteen different GWASs were analysed using a common set of ~2.4 million SNPs. The p -values for the common set of GWAS SNPs are plotted in dark green; p -values for SNPs that tag hypo-methylated DMRs are plotted in blue; and p -values for SNPs that tag hyper-methylated DMRs are plotted in pink. These DMRs are part of the great ape DMR dataset. ADHD, attention deficit hyperactivity disorder; BMI, body mass index; BPD, bipolar disorder; DBP, diastolic blood pressure; HDL, high density lipoprotein; LDL, low density lipoprotein; RA, rheumatoid arthritis; SBP, systolic blood pressure; SCZ, schizophrenia; TC, total cholesterol; TG, triglycerides. The MHC region was absent from the common set of SNPs. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)



Fig. 3. INRICH test for enrichment of association of DMR gene sets and NSS genes with SCZ, MHC masked. A visual heatmap depicting p -values from bootstrapping with 5000 iterations. The various evolutionary annotations compared are as follows. HypoDMR – human hypo-methylated DMRs; HyperDMR – human hyper-methylated DMRs. HypoDMR and HyperDMR were taken from the study by [Hernando-Herraez et al. \(2013\)](#). dmrH – human-specific DMRs ([Gokhman et al., 2014](#)), which are referred to as hominid DMRs in this manuscript. NSS – Neanderthal selective sweep. Datasets marked with * have been previously reported by ([Banerjee et al., 2018](#)) and are presented here for comparison only.

We also observed a similar trend for height where there was enrichment at SNPs of higher but not lower p -value thresholds. This enrichment was similarly less pronounced than for hominid DMRs (Supplementary Fig. 3).

4. Discussion

In our study, we investigated if regions of the human genome whose methylation has evolved since the divergence of modern humans from great apes are enriched for markers of schizophrenia. We found evidence that there is enrichment for hypo-methylated DMRs in the extended MHC locus, a known risk region that harbours the most significant schizophrenia GWAS markers ([Ripke et al., 2014](#)). When the MHC region was excluded from the analysis, there remained a trend towards enrichment of hypo-DMRs driven by SNPs of higher p -value thresholds but not genome wide p -value thresholds. This finding was complemented by the INRICH analyses that indicated significant enrichment among SNPs of higher p -value thresholds. However, in contrast to our previous finding, ([Banerjee et al., 2018](#)), the enrichment observed for hypo-DMRs is largely driven by the MHC region and not other genomic regions. In the previous paper ([Banerjee et al., 2018](#)), excluding the MHC region from analyses does not preclude genome-wide significant enrichment.

When analysing a global SNP list common to GWAS of several traits, we failed to find evidence of enrichment of any trait with the possible exception of height at higher SNP p -value thresholds. We tested this further with the INRICH pipeline, which revealed gene-level enrichment of LD intervals for height markers below the genome-wide threshold ($p < 5 \times 10e-8$). Compared to our previous study that analysed hominid DMRs ([Banerjee et al., 2018](#)), the great ape DMRs tested here show far less enrichment. The great ape and hominid DMRs have very little overlap, which suggests that the methylation changes that took place since the divergence of modern humans from Neanderthals and Denisovans occurred in different regions of the genome compared to those that took place since divergence from great apes.

The central role of the MHC region in the enrichment of human hypo-methylated regions poses interesting questions. The MHC region is known for its complex LD architecture, which renders the

interpretation of genetic signals very challenging. Other groups have previously reported that the MHC region is one of the fastest evolving regions of the human genome ([Meyer et al., 2017](#)) and have implicated it in mate preference ([Bernatchez and Landry, 2003](#); [Kromer et al., 2016](#); [Potts and Wakeland, 1990](#); [Roberts et al., 2008](#); [Winternitz et al., 2017](#)), odour perception ([Roberts et al., 2008](#); [Santos et al., 2005](#)) and immune response ([Benacerraf, 1981](#); [Horton et al., 2004](#)). Recently it was shown that a large proportion of the association of the region with schizophrenia can be explained by complement C4 haplotypes that include C4 copy number variation ([Sekar et al., 2016](#)). Nevertheless, there remains a part of the association in this region that is unexplained ([Gejman et al., 2011](#)) and will need further investigation. Furthermore, as reported by [Pouget et al. \(2016\)](#), compared to other autoimmune diseases, there is no enrichment of immune loci outside the MHC region in schizophrenia suggesting a highly localised enrichment of loci in this region. It is interesting to consider the possibility that the MHC region and the immune system in general play a central role in evolution at the epigenomic as well as at the genomic level ([Meyer et al., 2017](#); [Potts and Wakeland, 1990](#); [Sommer, 2005](#); [Traherne, 2008](#)). The mechanisms by which hypo-methylation could influence the aforementioned processes are open to speculation since the MHC region has >200 genes in close physical proximity and LD with one another ([Beck et al., 1999](#)). This makes it hard to interpret the exact biological consequences of our findings. In general, hypo-methylation usually is observed in active regions of the genome such as transcription start sites (TSS) while hyper-methylation is found in gene bodies ([Wagner et al., 2014](#)). One may speculate that a global shift in the methylation patterns of the extended MHC region towards hypo-methylation suggests higher activation of the genes contained therein. However, it is also known that hypo-methylation may in fact induce transcriptional repression ([Hon et al., 2012](#)). Future research should try to unravel the interplay between hypo and hyper-methylation in the regulation of the extended MHC region.

The immune system is also implicated in brain lateralization ([Meador et al., 2004](#); [Sumner et al., 2011](#)) and handedness ([Morfit and Weekes, 2001](#)) that are implicated in schizophrenia as well ([Venkatasubramanian and Debnath, 2014](#)). Recently it was shown that methylation of specific genes can predict handedness ([Schmitz](#)

et al., 2018). However, more research is needed to understand whether hypo-methylation in the extended MHC region affects handedness and brain lateralization. Since we analyse the dataset from the schizophrenia GWAS, all the sub-phenotypes associated with brain volume would be correlated with schizophrenia as well. Thus the genetic variants from the GWAS data also affect the broader phenotypic changes observed in patients with schizophrenia such as brain morphology (Lee et al., 2016; Smeland et al., 2017).

Interestingly, the gene-level analysis via INRICH seems to suggest enrichment of SNPs of higher p -value thresholds in great ape DMRs for both schizophrenia and height. This enrichment is far lower than what we found for hominid DMRs for both schizophrenia and height (Banerjee et al., 2018) and which persisted for schizophrenia even with pruned datasets. However, height and schizophrenia have a genetic overlap (Bacanu et al., 2013) and epidemiological studies have shown such genetic loci are discordant for direction of effect (Gunnell et al., 2005; Zammit et al., 2007). Future research should therefore, investigate whether the same genetic loci are driving the enrichment observed in both great ape and hominid DMRs for height and schizophrenia.

The very small overlap between great ape and hominid DMRs might suggest that the divergence from Neanderthals and Denisovans brought about more significant methylation changes in regions implicated in the aetiology of schizophrenia and height than the divergence from great apes. In other words, our results might suggest that the evolutionary factors that regulate methylation variation acted on different segments of the genome at different time points. So while the methylation variation since the divergence from Neanderthals and Denisovans may mark a genome-wide increase of schizophrenia susceptibility (Banerjee et al., 2018), the methylation variation from the time period between 13 and 6 MYA appears not to have significantly increased the risk for schizophrenia (except possibly for some markers in the MHC region).

Our results are also in line with the findings of (Srinivasan et al., 2017), who failed to find evidence of enrichment of schizophrenia using genomic markers of evolution dating back to 200 MYA. Bigdeli et al. (2013) came to a similar conclusion using genomic markers of evolution derived from great apes that failed to show enrichment for schizophrenia causal variants. In contrast, evidence exists of enrichment of regions of recent human evolution for schizophrenia variants, possibly from the time of divergence of common ancestors of humans and Neanderthals (Srinivasan et al., 2016). Interestingly, one of the evolutionary proxies used by Srinivasan et al. (2017), namely HARs, also showed enrichment for height, similar to our recent study (Banerjee et al., 2018). This may suggest that regions controlling both genomic and epigenomic variation in height may also be driven by recent evolution. Finally, our results agree well with the observation by (Srinivasan et al., 2017) of some involvement of the MHC in an early evolutionary context.

Although our results are in line with several findings in the field, the current methods have some limitations. Highly polygenic traits such as schizophrenia have a large number of genetic loci contributing to the aetiology of a disease (Bulik-Sullivan et al., 2015; Schork et al., 2016). The ability to detect these large numbers of genetic loci is dependent on the sample size and adequate statistical power (Schork et al., 2016). Consequently, the polygenic enrichment methods may be limited by the statistical power of the respective GWAS and trait polygenicity. Furthermore, in the INRICH analysis that uses LD-clumping of SNPs at $p < 10e-3$ to $p < 10e-8$, higher p -value thresholds (e.g. $p < 10e-3$) still include SNPs of lower p -values, even though they become progressively smaller minorities. Thus, although higher p -values increase the number of LD-clumps tested, we do not expect this to increase the Type I error rate (Lee et al., 2012).

Research into methylation of schizophrenia has revealed that patients tend to have widespread aberrant methylation (Hannon et al., 2016; Jaffe et al., 2016) with local hyper-methylation of specific genes (Yasui et al., 2016) and that antipsychotic administration partially

reverses the global hypo-methylation (Yasui et al., 2016). To determine whether the evolutionary methylated regions in the form of great ape and hominid DMRs also play a role in the aetiology of the disease, future research should investigate their methylation status in actual patient samples.

In conclusion, our results suggest that methylation markers tracing an evolutionary period dating back to 13 MYA (great ape DMRs) are not enriched for schizophrenia markers, unlike methylation markers from a recent timeframe (hominid DMRs) (Banerjee et al., 2018). Taken in consideration with previous studies of genomic markers of evolution dating back 200 MYA (Srinivasan et al., 2017), our results help narrow down the evolutionary window of the origins of schizophrenia to more recent evolutionary events, possibly after the divergence of modern-day humans from Neanderthals and Denisovans. Using epigenomics approaches, we therefore help refine the evolutionary hypothesis of schizophrenia as posited by T.J Crow and provide evidence to evolution playing a role in the persistence of schizophrenia.

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.schres.2018.11.025>.

Conflict of interest

All authors declare that they have no conflicts of interest.

Contributors

NB and SLH designed and conceived the study. NB carried out the data analysis, interpretation and wrote the first draft of the manuscript. TP contributed to the data analysis of the study. FB contributed with data. VMS, OAA, FB and SLH critically revised the manuscript. All authors contributed to and approved the final manuscript.

Role of the funding source

The study was supported by a grant from by Norges Forskningsråd (#2 T23273) and the KG Jebsen Foundation (SKGJ-MED-008) to OAA. The funding bodies had no role in the analyses or writing of the manuscript, or the decision to submit this work for publication.

Acknowledgement

We thank Andrew J. Schork PhD for providing assistance with the code for LD-pruning. We would also like to thank Isabel Hanson Scientific Writing for help with proof-reading and formatting of the manuscript.

References

- Ayuso-Mateos, J.L., 2002. Global Burden of Schizophrenia in the Year 2000-Version 1 Estimates. World Health Organization.
- Bacanu, S.-A., Chen, X., Kendler, K.S., 2013. The genetic overlap between schizophrenia and height. *Schizophr. Res.* 151, 226–228. <https://doi.org/10.1016/j.schres.2013.10.016>.
- Banerjee, N., Polushina, T., Bettella, F., Giddaluru, S., Steen, V.M., Andreassen, O.A., Le Hellard, S., 2018. Recently evolved human-specific methylated regions are enriched in schizophrenia signals. *BMC Evol. Biol.* 18.
- Bassett, A.S., Bury, A., Hodgkinson, K.A., Honer, W.G., 1996. Reproductive fitness in familial schizophrenia. *Schizophr. Res.* 21, 151–160.
- Beck, S., Geraghty, D., Inoko, H., Rowen, L., 1999. Complete sequence and gene map of a human major histocompatibility complex. *Nature* 401, 921–923.
- Benacerraf, B., 1981. Role of MHC gene products in immune regulation. *Science* 212, 1229–1238.
- Bernatchez, L., Landry, C., 2003. MHC studies in nonmodel vertebrates: what have we learned about natural selection in 15 years? *J. Evol. Biol.* 16, 363–377.
- Bernstein, B.E., Meissner, A., Lander, E.S., 2007. The mammalian epigenome. *Cell* 128, 669–681. <https://doi.org/10.1016/j.cell.2007.01.033>.
- Bigdeli, T.B., Fanous, A.H., Riley, B.P., Reimers, M., Chen, X., Kendler, K.S., Bacanu, S.-A., 2013. On schizophrenia as a “disease of humanity”. *Schizophr. Res.* 143, 223–224. <https://doi.org/10.1016/j.schres.2012.10.036>.
- Bird, C.P., Stranger, B.E., Liu, M., Thomas, D.J., Ingle, C.E., Beazley, C., Miller, W., Hurles, M.E., Dermitzakis, E.T., 2007. Fast-evolving noncoding sequences in the human genome. *Genome Biol.* 8, R118.
- Brown, S., 1997. Excess mortality of schizophrenia. A meta-analysis. *Br. J. Psychiatry* 171, 502–508.
- Brüne, M., 2004. Schizophrenia—an evolutionary enigma? *Neurosci. Biobehav. Rev.* 28, 41–53.
- Bulik-Sullivan, B.K., Loh, P.-R., Finucane, H.K., Ripke, S., Yang, J., Patterson, N., Daly, M.J., Price, A.L., Neale, B.M., Consortium, S.W.G. of the P.G. et al., 2015. LD Score regression distinguishes confounding from polygenicity in genome-wide association studies. *Nat. Genet.* 47, 291.

- Burbano, H.A., Hodges, E., Green, R.E., Briggs, A.W., Krause, J., Meyer, M., Good, J.M., Maricic, T., Johnson, P.L.F., Xuan, Z., Rooks, M., Bhattacharjee, A., Brizuela, L., Albert, F.W., de la Silla, M., Fortea, J., Rosas, A., Lachmann, M., Hannon, G.J., Pääbo, S., 2010. Targeted investigation of the Neanderthal genome by array-based sequence capture. *Science* 328, 723–725. <https://doi.org/10.1126/science.1188046>.
- Bush, E.C., Lahn, B.T., 2008. A genome-wide screen for noncoding elements important in primate evolution. *BMC Evol. Biol.* 8, 17.
- Cardo, A.G., Marshall, E.J., Coid, B., Macdonald, A.M., Ribchester, T.R., Davies, N.J., Venturi, P., Jones, L.A., Lewis, S.W., Sham, P.C., et al., 1999. Heritability estimates for psychotic disorders: the Maudsley twin psychosis series. *Arch. Gen. Psychiatry* 56, 162–168.
- Christoforou, A., Dondrup, M., Mattingsdal, M., Mattheisen, M., Giddaluru, S., Nöthen, M.M., Rietschel, M., Cichon, S., Djurovic, S., Andreassen, O.A., et al., 2012. Linkage-disequilibrium-based binning affects the interpretation of GWASs. *Am. J. Hum. Genet.* 90, 727–733.
- Crespi, B., Summers, K., Dorus, S., 2007. Adaptive evolution of genes underlying schizophrenia. *Proc. R. Soc. Lond.* 274, 2801–2810.
- Crow, T.J., 1995. A Darwinian approach to the origins of psychosis. *Br. J. Psychiatry* 167, 12–25.
- Crow, T.J., 1997. Is schizophrenia the price that *Homo sapiens* pays for language? *Schizophr. Res.* 28, 127–141.
- Crow, T.J., 2000. Schizophrenia as the price that *Homo sapiens* pays for language: a resolution of the central paradox in the origin of the species. *Brain Res. Rev.* 31, 118–129.
- Crow, T.J., 2008. The ‘big bang’ theory of the origin of psychosis and the faculty of language. *Schizophr. Res.* 102, 31–52.
- Demonitis, D., Walters, R.K., Martin, J., Mattheisen, M., Als, T.D., Agerbo, E., Belliveau, R., Bybjerg-Grauholm, J., Bækved-Hansen, M., Cerrato, F., et al., 2017. Discovery of the First Genome-wide Significant Risk Loci for ADHD (bioRxiv 145581).
- Durbin, R., Abecasis, G., Bentley, D., Chakravarti, A., Clark, A., Donnelly, P., Eichler, E., Flicek, P., Gabriel, S., Gibbs, R., et al., 2012. An integrated map of genetic variation from 1,092 human genomes. *Nature* 491.
- Ehret, G.B., Munroe, P.B., Rice, K.M., Bochud, M., Johnson, A.D., Chasman, D.I., Smith, A.V., Tobin, M.D., Verwoert, G.C., Hwang, S.-J., et al., 2011. Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. *Nature* 478, 103.
- Essen-Möller, E., 1959. Mating and fertility patterns in families with schizophrenia. *Eugenics Quarterly* 6, 142–147.
- Gejman, P.V., Sanders, A.R., Kendler, K.S., 2011. Genetics of schizophrenia: new findings and challenges. *Annu. Rev. Genomics Hum. Genet.* 12, 121–144. <https://doi.org/10.1146/annurev-genom-082410-101459>.
- Gittelman, R.M., Hun, E., Ay, F., Madeoy, J., Pennacchio, L., Noble, W.S., Hawkins, R.D., Akey, J.M., 2015. Comprehensive identification and analysis of human accelerated regulatory DNA. *Genome Res.* 25, 1245–1255.
- Glazko, G.V., Nei, M., 2003. Estimation of divergence times for major lineages of primate species. *Mol. Biol. Evol.* 20, 424–434.
- Gokhman, D., Lavi, E., Prüfer, K., Fraga, M.F., Riancho, J.A., Kelso, J., Pääbo, S., Meshorer, E., Carmel, L., 2014. Reconstructing the DNA methylation maps of the Neanderthal and the Denisovan. *Science* 344, 523–527.
- Green, R.E., Krause, J., Briggs, A.W., Maricic, T., Stenzel, U., Kircher, M., Patterson, N., Li, H., Zhai, W., Fritz, M.H.-Y., et al., 2010. A draft sequence of the Neanderthal genome. *Science* 328, 710–722.
- Gunnell, D., Harrison, G., Whitley, E., Lewis, G., Tynelius, P., Rasmussen, F., 2005. The association of fetal and childhood growth with risk of schizophrenia. Cohort study of 720,000 Swedish men and women. *Schizophr. Res.* 79, 315–322.
- Hannon, E., Dempster, E., Viana, J., Burrage, J., Smith, A.R., Macdonald, R., St Clair, D., Mustard, C., Breen, G., Therman, S., et al., 2016. An integrated genetic-epigenetic analysis of schizophrenia: evidence for co-localization of genetic associations and differential DNA methylation. *Genome Biol.* 17, 176.
- Hasegawa, M., Kishino, H., Yano, T., 1985. Dating of the human-ape splitting by a molecular clock of mitochondrial DNA. *J. Mol. Evol.* 22, 160–174.
- Hernando-Herraez, I., Prado-Martinez, J., Garg, P., Fernandez-Callejo, M., Heyn, H., Hvilson, C., Navarro, A., Esteller, M., Sharp, A.J., Marques-Bonet, T., 2013. Dynamics of DNA methylation in recent human and great ape evolution. *PLoS Genet.* 9, e1003763.
- Hernando-Herraez, I., Heyn, H., Fernandez-Callejo, M., Vidal, E., Fernandez-Bellon, H., Prado-Martinez, J., Sharp, A.J., Esteller, M., Marques-Bonet, T., 2015. The interplay between DNA methylation and sequence divergence in recent human evolution. *Nucleic Acids Res.* 43, 8204–8214.
- Hon, G.C., Hawkins, R.D., Caballero, O.L., Lo, C., Lister, R., Pelizzola, M., Valsesia, A., Ye, Z., Kuan, S., Edsall, L.E., Camargo, A.A., Stevenson, B.J., Ecker, J.R., Bafna, V., Strausberg, R.L., Simpson, A.J., Ren, B., 2012. Global DNA hypomethylation coupled to repressive chromatin domain formation and gene silencing in breast cancer. *Genome Res.* 22, 246–258. <https://doi.org/10.1101/gr.125872.111>.
- Horton, R., Wilming, L., Rand, V., Lovering, R.C., Bruford, E.A., Khodiyar, V.K., Lush, M.J., Povey, S., Talbot Jr., C.C., Wright, M.W., et al., 2004. Gene map of the extended human MHC. *Nature reviews. Genetics* 5, 889.
- Huxley, J., Mayr, E., Osmond, H., Hoffer, A., 1964. Schizophrenia as a genetic morphism. *Nature* 204, 220–221.
- Jaffe, A.E., Gao, Y., Deep-Soboslay, A., Tao, R., Hyde, T.M., Weinberger, D.R., Kleinman, J.E., 2016. Mapping DNA methylation across development, genotype and schizophrenia in the human frontal cortex. *Nat. Neurosci.* 19, 40.
- Jeste, D.V., Del Carmen, R., Lohr, J.B., Wyatt, R.J., 1985. Did schizophrenia exist before the eighteenth century? *Compr. Psychiatry* 26, 493–503.
- Karolchik, D., Barber, G.P., Casper, J., Clawson, H., Cline, M.S., Diekhans, M., Dreszer, T.R., Fujita, P.A., Gurusvaido, L., Haussler, M., Harte, R.A., Heitner, S., Hinrichs, A.S., Learned, K., Lee, B.T., Li, C.H., Raney, B.J., Rhead, B., Rosenbloom, K.R., Sloan, C.A., Speir, M.L., Zweig, A.S., Haussler, D., Kuhn, R.M., Kent, W.J., 2014. The UCSC Genome Browser database: 2014 update. *Nucleic Acids Res.* 42, D764–D770. <https://doi.org/10.1093/nar/gkt1168>.
- Kromer, J., Hummel, T., Pietrowski, D., Giani, A., Sauter, J., Ehninger, G., Schmidt, A., Croy, I., 2016. Influence of HLA on human partnership and sexual satisfaction. *Sci. Rep.* 6, 32550.
- Kundaje, A., Meuleman, W., Ernst, J., Bilenky, M., Yen, A., Heravi-Moussavi, A., Kheradpour, P., Zhang, Z., Wang, J., Ziller, M.J., et al., 2015. Integrative analysis of 111 reference human epigenomes. *Nature* 518, 317–330.
- Kyaga, S., Lichtenstein, P., Boman, M., Hultman, C., Långström, N., Landén, M., 2011. Creativity and mental disorder: family study of 300 000 people with severe mental disorder. *Br. J. Psychiatry* 199, 373–379.
- Lander, E.S., Linton, L.M., Birren, B., Nussbaum, C., Zody, M.C., Baldwin, J., Devon, K., Dewar, K., Doyle, M., FitzHugh, W., et al., 2001. Initial Sequencing and Analysis of the Human Genome.
- Langergraber, K.E., Prüfer, K., Rowney, C., Boesch, C., Crockford, C., Fawcett, K., Inoue, E., Inoue-Muruyama, M., Mitani, J.C., Muller, M.N., Robbins, M.M., Schubert, G., Stoinski, T.S., Viola, B., Watts, D., Wittig, R.M., Wrangham, R.W., Zuberbühler, K., Pääbo, S., Vigilant, L., 2012. Generation times in wild chimpanzees and gorillas suggest earlier divergence times in great ape and human evolution. *Proc. Natl. Acad. Sci. U.S.A.* 109, 15716–15721.
- Larson, C.A., Nyman, G.E., 1973. Differential fertility in schizophrenia. *Acta Psychiatr. Scand.* 49, 272–280.
- Lee, P.H., O’Dushlaine, C., Thomas, B., Purcell, S.M., 2012. INRICH: interval-based enrichment analysis for genome-wide association studies. *Bioinformatics* 28, 1797–1799. <https://doi.org/10.1093/bioinformatics/bts191>.
- Lee, P.H., Baker, J.T., Holmes, A.J., Jahanshad, N., Ge, T., Jung, J.-Y., Cruz, Y., Manoach, D.S., Hibar, D.P., Faskowitz, J., et al., 2016. Partitioning heritability analysis reveals a shared genetic basis of brain anatomy and schizophrenia. *Mol. Psychiatry* 21, 1680.
- Lewis, A., 1958. Fertility and mental illness. *Eugen. Rev.* 50, 91–106.
- Lichtenstein, P., Yip, B.H., Björk, C., Pawitan, Y., Cannon, T.D., Sullivan, P.F., Hultman, C.M., 2009. Common genetic determinants of schizophrenia and bipolar disorder in Swedish families: a population-based study. *Lancet* 373, 234–239.
- Locke, A.E., Kahali, B., Berndt, S.I., Justice, A.E., Pers, T.H., Day, F.R., Powell, C., Vedantam, S., Buchkovich, M.L., Yang, J., et al., 2015. Genetic studies of body mass index yield new insights for obesity biology. *Nature* 518, 197–206.
- Macrosley, K., 1963. An investigation into the fertility rates of mentally ill patients. *Ann. Hum. Genet.* 27, 247–256.
- Markow, T.A., 2012. Developmental instability: its origins and evolutionary implications. *Proceedings of the International Conference on Developmental Instability: Its Origins and Evolutionary Implications*, Tempe, Arizona, 14–15 June 1993. Springer Science & Business Media.
- Meador, K.J., Loring, D.W., Ray, P.G., Helman, S.W., Vazquez, B.R., Neveu, P.J., 2004. Role of cerebral lateralization in control of immune processes in humans. *Ann. Neurol.* 55, 840–844.
- Mendizabal, I., Keller, T., Zeng, J., Soojin, V.Y., 2014. Epigenetics and evolution. *Integr. Comp. Biol.* 54, 31–42.
- Messias, E.L., Chen, C.-Y., Eaton, W.W., 2007. Epidemiology of schizophrenia: review of findings and myths. *Psychiatr. Clin. North Am.* 30, 323–338.
- Meyer, D., Aguiar, V.R., Bitarello, B.D., Brandt, D.Y., Nunes, K., 2017. A genomic perspective on HLA evolution. *Immunogenetics* 1–23.
- Molaro, A., Hodges, E., Fang, F., Song, Q., McCombie, W.R., Hannon, G.J., Smith, A.D., 2011. Sperm methylation profiles reveal features of epigenetic inheritance and evolution in primates. *Cell* 146, 1029–1041.
- Morfit, N., Weekes, N., 2001. Handedness and immune function. *Brain Cogn.* 46, 209–213.
- Nichols, C., 2009. Is there an evolutionary advantage of schizophrenia? *Personal. Individ. Differ.* 46, 832–838.
- Paaby, A.B., Rockman, M.V., June 1990. Cryptic genetic variation: evolution’s hidden substrate. *Nat. Rev. Genet.* 5, 181–187.
- Pollard, K.S., Salama, S.R., King, B., Kern, A.D., Dreszer, T., Katzman, S., Siepel, A., Pedersen, J.S., Bejerano, G., Baertsch, R., et al., 2006. Forces shaping the fastest evolving regions in the human genome. *PLoS Genet.* 2, e168.
- Potts, W.K., Wakeland, E.K., 1990. Evolution of diversity at the major histocompatibility complex. *Trends Ecol. Evol.* 5, 181–187. [https://doi.org/10.1016/0169-5347\(90\)90207-T](https://doi.org/10.1016/0169-5347(90)90207-T).
- Pouget, J.G., Gonçalves, V.F., Consortium, S.W.G. of the P.G. Spain, S.L., Finucane, H.K., Raychaudhuri, S., Kennedy, J.L., Knight, J., 2016. Genome-wide association studies suggest limited immune gene enrichment in schizophrenia compared to 5 autoimmune diseases. *Schizophr. Bull.* 42, 1176–1184.
- Power, R.A., Kyaga, S., Uher, R., MacCabe, J.H., Långström, N., Landén, M., McGuffin, P., Lewis, C.M., Lichtenstein, P., Svensson, A.C., 2013. Fecundity of patients with schizophrenia, autism, bipolar disorder, depression, anxiety, or substance abuse vs their unaffected siblings. *JAMA Psychiatry* 70, 22–30.
- Rannala, B., Yang, Z., 2003. Bayes estimation of species divergence times and ancestral population sizes using DNA sequences from multiple loci. *Genetics* 164, 1645–1656.
- Ripke, S., Neale, B.M., Corvin, A., Walters, J.T., Farh, K.-H., Holmans, P.A., Lee, P., Bulik-Sullivan, B., Collier, D.A., Huang, H., et al., 2014. Biological insights from 108 schizophrenia-associated genetic loci. *Nature* 511, 421.
- Rivera, C.M., Ren, B., 2013. Mapping human epigenomes. *Cell* 155, 39–55. <https://doi.org/10.1016/j.cell.2013.09.011>.
- Roberts, S.C., Gosling, L.M., Carter, V., Petrie, M., 2008. MHC-correlated odour preferences in humans and the use of oral contraceptives. *Proc. Biol. Sci.* 275, 2715–2722. <https://doi.org/10.1098/rspb.2008.0825>.
- Santos, P.S.C., Schinemborn, J.A., Gabardo, J., Bicalho, M. da G., 2005. New evidence that the MHC influences odor perception in humans: a study with 58 Southern Brazilian students. *Horm. Behav.* 47, 384–388.

- Schmitz, J., Kumsta, R., Moser, D., Güntürkün, O., Ocklenburg, S., 2018. DNA methylation in candidate genes for handedness predicts handedness direction. *Laterality* 23, 441–461.
- Schork, A.J., Thompson, W.K., Pham, P., Torkamani, A., Roddey, J.C., Sullivan, P.F., Kelsoe, J.R., O'Donovan, M.C., Furberg, H., Schork, N.J., et al., 2013. All SNPs are not created equal: genome-wide association studies reveal a consistent pattern of enrichment among functionally annotated SNPs. *PLoS Genet.* e1003449, 9.
- Schork, A.J., Wang, Y., Thompson, W.K., Dale, A.M., Andreassen, O.A., 2016. New statistical approaches exploit the polygenic architecture of schizophrenia—implications for the underlying neurobiology. *Curr. Opin. Neurobiol.* 36, 89–98.
- Sekar, A., Bialas, A.R., de Rivera, H., Davis, A., Hammond, T.R., Kamitaki, N., Tooley, K., Presumey, J., Baum, M., Van Doren, V., et al., 2016. Schizophrenia risk from complex variation of complement component 4. *Nature* 530, 177–183.
- Sklar, P., Ripke, S., Scott, L.J., Andreassen, O.A., Cichon, S., Craddock, N., Edenberg, H.J., Nurnberger, J.I., Rietschel, M., Blackwood, D., et al., 2011. Large-scale genome-wide association analysis of bipolar disorder identifies a new susceptibility locus near ODZ4. *Nat. Genet.* 43, 977–983.
- Skre, I., Onstad, S., Torgersen, S., Lygren, S., Kringlen, E., 1993. A twin study of DSM-III-R anxiety disorders. *Acta Psychiatr. Scand.* 88, 85–92.
- Smeland, O.B., Wang, Y., Frei, O., Li, W., Hibar, D.P., Franke, B., Bettella, F., Witoelar, A., Djurovic, S., Chen, C.-H., et al., 2017. Genetic overlap between schizophrenia and volumes of hippocampus, putamen, and intracranial volume indicates shared molecular genetic mechanisms. *Schizophr. Bull.* 44, 854–864.
- Sniekers, S., Stringer, S., Watanabe, K., Jansen, P.R., Coleman, J.R., Krapohl, E., Taskesen, E., Hammerschlag, A.R., Okbay, A., Zabaneh, D., et al., 2017. Genome-wide association meta-analysis of 78,308 individuals identifies new loci and genes influencing human intelligence. *Nat. Genet.* 49, 1107–1112.
- Sommer, S., 2005. The importance of immune gene variability (MHC) in evolutionary ecology and conservation. *Front. Zool.* 2, 16.
- Srinivasan, S., Bettella, F., Mattingsdal, M., Wang, Y., Witoelar, A., Schork, A.J., Thompson, W.K., Zuber, V., Winsvold, B.S., Zwart, J.-A., et al., 15 August 2016. Genetic markers of human evolution are enriched in schizophrenia. *Biol. Psychiatry* 80 (4), 284–292.
- Srinivasan, S., Bettella, F., Hassani, S., Wang, Y., Witoelar, A., Schork, A.J., Thompson, W.K., Collier, D.A., Desikan, R.S., Melle, I., et al., 2017. Probing the association between early evolutionary markers and schizophrenia. *PLoS One* 12 (e0169227).
- Stahl, E.A., Raychaudhuri, S., Remmers, E.F., Xie, G., Eyre, S., Thomson, B.P., Li, Y., Kurreeman, F.A., Zernakova, A., Hinks, A., et al., 2010. Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. *Nat. Genet.* 42, 508–514.
- Stevens, B.C., 1969. Marriage and Fertility of Women Suffering From Schizophrenia or Affective Disorders. Oxford UP.
- Sullivan, P.F., Kendler, K.S., Neale, M.C., 2003. Schizophrenia as a complex trait: evidence from a meta-analysis of twin studies. *Arch. Gen. Psychiatry* 60, 1187–1192.
- Sumner, R.C., Parton, A., Nowicky, A.V., Kishore, U., Gidron, Y., 2011. Hemispheric lateralisation and immune function: a systematic review of human research. *J. Neuroimmunol.* 240, 1–12.
- Team, R.C., 2017. R: A Language and Environment for Statistical Computing (Vienna, Austria).
- Teslovich, T.M., Musunuru, K., Smith, A.V., Edmondson, A.C., Stylianou, I.M., Koseki, M., Pirruccello, J.P., Ripatti, S., Chasman, D.I., Willer, C.J., Johansen, C.T., Fouchier, S.W., Isaacs, A., Peloso, G.M., Barbalic, M., Ricketts, S.L., Bis, J.C., Aulchenko, Y.S., Thorleifsson, G., Feitosa, M.F., Chambers, J., Orho-Melander, M., Melander, O., Johnson, T., Li, X., Guo, X., Li, M., Shin Cho, Y., Jin Go, M., Jin Kim, Y., Lee, J.-Y., Park, T., Kim, K., Sim, X., Twee-Hee Ong, R., Croteau-Chonka, D.C., Lange, L.A., Smith, J.D., Song, K., Hua Zhao, J., Yuan, X., Luan, J., Lamina, C., Ziegler, A., Zhang, W., Zee, R.Y.L., Wright, A.F., Witteman, J.C.M., Wilson, J.F., Willemsen, G., Wichmann, H.-E., Whitfield, J.B., Waterworth, D.M., Wareham, N.J., Waeber, G., Vollenweider, P., Voight, B.F., Vitart, V., Uitterlinden, A.G., Uda, M., Tuomilehto, J., Thompson, J.R., Tanaka, T., Surakka, I., Stringham, H.M., Spector, T.D., Soranzo, N., Smit, J.H., Sinisalo, J., Silander, K., Sijbrands, E.J.G., Scuteri, A., Scott, J., Schlessinger, D., Sanna, S., Salomaa, V., Saharinen, J., Sabatti, C., Ruukonen, A., Rudan, I., Rose, L.M., Roberts, R., Rieder, M., Psaty, B.M., Pramstaller, P.P., Pichler, I., Perola, M., Penninx, B.W.J.H., Pedersen, N.L., Pattaro, C., Parker, A.N., Pare, G., Oostra, B.A., O'Donnell, C.J., Nieminen, M.S., Nickerson, D.A., Montgomery, G.W., Meitinger, T., McPherson, R., McCarthy, M.I., McArdle, W., Masson, D., Martin, N.G., Marroni, F., Mangino, M., Magnusson, P.K.E., Lucas, G., Luben, R., Loos, R.J.F., Lokki, M.-L., Lettre, G., Langenberg, C., Launer, L.J., Lakatta, E.G., Laaksonen, R., Kyvik, K.O., Kronenberg, F., König, I.R., Khaw, K.-T., Kaprio, J., Kaplan, L.M., Johansson, A., Jarvelin, M.-R., Janssens, A.C.J.W., Ingelsson, E., Igl, W., Kees Hovingh, G., Hottenga, J.-J., Hofman, A., Hicks, A.A., Hengstenberg, C., Heid, I.M., Hayward, C., Havulinna, A.S., Hastie, N.D., Harris, T.B., Haritunians, T., Hall, A.S., Gyllenstein, U., Guiducci, C., Groop, L.C., Gonzalez, E., Gieger, C., Freimer, N.B., Ferrucci, L., Erdmann, J., Elliott, P., Ejebe, K.G., Döring, A., Dominiczak, A.F., Demissie, S., Deloukas, P., de Geus, E.J.C., de Faire, U., Crawford, G., Collins, F.S., Chen, Y.I., Caulfield, M.J., Campbell, H., Burt, N.P., Bonnycastle, L.L., Boomsma, D.I., Boekholdt, S.M., Bergman, R.N., Barroso, I., Bandinelli, S., Ballantyne, C.M., Assimes, T.L., Quertermous, T., Altshuler, D., Seielstad, M., Wong, T.Y., Tai, E.-S., Feranil, A.B., Kuzawa, C.W., Adair, L.S., Taylor, H.A., Borecki, I.B., Gabriel, S.B., Wilson, J.G., Holm, H., Thorsteinsdottir, U., Gudnason, V., Krauss, R.M., Mohlke, K.L., Ordovas, J.M., Munroe, P.B., Kooner, J.S., Tall, A.R., Hegele, R.A., Kastelein, J.J.P., Schadt, E.E., Rotter, J.I., Boerwinkle, E., Strachan, D.P., Mooser, V., Stefansson, K., Reilly, M.P., Samani, N.J., Schunkert, H., Cupples, L.A., Sandhu, M.S., Ridker, P.M., Rader, D.J., van Duijn, C.M., Peltonen, L., Abecasis, G.R., Boehnke, M., Kathiresan, S., 2010. Biological, clinical and population relevance of 95 loci for blood lipids. *Nature* 466, 707–713. <https://doi.org/10.1038/nature09270>.
- Traherne, J., 2008. Human MHC architecture and evolution: implications for disease association studies. *Int. J. Immunogenet.* 35, 179–192.
- Venkatasubramanian, G., Debnath, M., 2014. Neuroimmunological aberrations and cerebral asymmetry abnormalities in schizophrenia: Select perspectives on pathogenesis. *Clin. Psychopharmacol. Neurosci.* 12, 8.
- Venter, J.C., Adams, M.D., Myers, E.W., Li, P.W., Mural, R.J., Sutton, G.G., Smith, H.O., Yandell, M., Evans, C.A., Holt, R.A., et al., 2001. The sequence of the human genome. *Science* 291, 1304–1351.
- Wagner, J.R., Busche, S., Ge, B., Kwan, T., Pastinen, T., Blanchette, M., 2014. The relationship between DNA methylation, genetic and expression inter-individual variation in untransformed human fibroblasts. *Genome Biol.* 15, R37.
- WHO, 1973. Report of the International Pilot Study of Schizophrenia.
- Winternitz, J., Abbate, J., Huchard, E., Havlíčková, J., Garamszegi, L., 2017. Patterns of MHC-dependent mate selection in humans and nonhuman primates: a meta-analysis. *Mol. Ecol.* 26, 668–688.
- Wood, A.R., Esko, T., Yang, J., Vedantam, S., Pers, T.H., Gustafsson, S., Chu, A.Y., Estrada, K., Luan, J., Kutalik, Z., et al., 2014. Defining the role of common variation in the genomic and biological architecture of adult human height. *Nat. Genet.* 46, 1173–1186.
- Xu, K., Schadt, E.E., Pollard, K.S., Roussos, P., Dudley, J.T., 2015. Genomic and network patterns of schizophrenia genetic variation in human evolutionary accelerated regions. *Mol. Biol. Evol.* 32, 1148–1160.
- Yasui, D., Peedicayil, J., Grayson, D.R., 2016. *Neuropsychiatric Disorders and Epigenetics*. Academic Press.
- Zammit, S., Rasmussen, F., Farahmand, B., Gunnell, D., Lewis, G., Tynelius, P., Broberg, G., 2007. Height and body mass index in young adulthood and risk of schizophrenia: a longitudinal study of 1 347 520 Swedish men. *Acta Psychiatr. Scand.* 116, 378–385.